Athlete's Foot Firm Kicks Back On NAD Finding That Brand Is A Fungal Claim
This article was originally published in The Pink Sheet
Executive Summary
Kramer Laboratories' claims for Fungi-Nail athlete's foot product referred to FDA and FTC after it refuses to comply with NAD's recommendation to modify the name. The firm, which agreed to modify packaging and commercial claims, was warned by FDA about the brand in 2005.
You may also be interested in...
Advantice Connects On Second Swing To Support Nail Fungus Claims Challenged By Arcadia
Without study it conducted after first review, Advantice wouldn’t have changed NAD’s conclusion on firm’s claim its product “starts improving nail appearance in just 2 days.” Without Arcadia’s premature publication of recommendation following NAD’s first review, Advantice wouldn’t have second chance.
Vaccination Health Next Stop For Dentovations’ Self+ Immunity Supplement Line
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.
NAD Issues Latest Decision In Fungal Nail Brands’ Claims Feud
Three years ago, the Kerasal fungal nail brand brought a challenge to the National Advertising Division that decimated claims for competing Fungi-Nail products and got federal agencies involved. The shoe is now on the other foot, as the NAD agrees with Fungi-Nail that a slew of Kerasal claims should be discontinued.